# Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer

> **NCT00201708** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 56 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide (AC)

## Key facts

- **NCT ID:** NCT00201708
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2006-12
- **Final completion:** 2014-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2016-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00201708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00201708, "Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT00201708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*